+

WO2002058724A8 - Utilisation de lp82 pour traiter les problemes de poids - Google Patents

Utilisation de lp82 pour traiter les problemes de poids

Info

Publication number
WO2002058724A8
WO2002058724A8 PCT/US2002/000498 US0200498W WO02058724A8 WO 2002058724 A8 WO2002058724 A8 WO 2002058724A8 US 0200498 W US0200498 W US 0200498W WO 02058724 A8 WO02058724 A8 WO 02058724A8
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
weight disorders
treat body
relates
present
Prior art date
Application number
PCT/US2002/000498
Other languages
English (en)
Other versions
WO2002058724A2 (fr
WO2002058724A3 (fr
Inventor
Niles Wayne Fox
Original Assignee
Lilly Co Eli
Niles Wayne Fox
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Niles Wayne Fox filed Critical Lilly Co Eli
Priority to US10/466,695 priority Critical patent/US20040162237A1/en
Priority to EP02720768A priority patent/EP1390060A2/fr
Publication of WO2002058724A2 publication Critical patent/WO2002058724A2/fr
Publication of WO2002058724A3 publication Critical patent/WO2002058724A3/fr
Publication of WO2002058724A8 publication Critical patent/WO2002058724A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

L'invention porte sur un gène de mammifère intervenant dans le traitement des problèmes de poids, et plus spécifiquement sur les procédés d'utilisation de compositions à base de polynucléotides LP82, de polypeptides LP82, et/ou d'anticorps LP82, en vue de la prévention et/ou du traitement chez les mammifères de problèmes de poids, dont l'obésité, la cachexie, et l'anorexie.
PCT/US2002/000498 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids WO2002058724A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/466,695 US20040162237A1 (en) 2002-01-15 2002-01-15 Use of lp82 to treat body weight disorders
EP02720768A EP1390060A2 (fr) 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26423901P 2001-01-26 2001-01-26
US60/264,239 2001-01-26

Publications (3)

Publication Number Publication Date
WO2002058724A2 WO2002058724A2 (fr) 2002-08-01
WO2002058724A3 WO2002058724A3 (fr) 2003-12-18
WO2002058724A8 true WO2002058724A8 (fr) 2004-05-21

Family

ID=23005167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000498 WO2002058724A2 (fr) 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids

Country Status (2)

Country Link
EP (1) EP1390060A2 (fr)
WO (1) WO2002058724A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547525T1 (de) 2000-08-08 2012-03-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
ATE460429T1 (de) 2000-09-15 2010-03-15 Zymogenetics Inc Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
CA2746308A1 (fr) 2001-12-17 2003-06-26 Zymogenetics, Inc. Methode permettant de traiter l'infection par le virus du papillome humain
EA009124B1 (ru) 2003-03-24 2007-10-26 Займоджинетикс, Инк. Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
JP2007501813A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ 新生血管形成と関連した症状を治療および診断するためのインターロイキン−２０
CA2545867A1 (fr) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps et partenaires de liaison anti-il 20 et procedes d'utilisation dans l'inflammation
CN101198625A (zh) 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其在炎症中的使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CN1618969A (zh) * 1997-11-26 2005-05-25 津莫吉尼蒂克斯公司 哺乳动物细胞因子样多肽－10

Also Published As

Publication number Publication date
WO2002058724A2 (fr) 2002-08-01
WO2002058724A3 (fr) 2003-12-18
EP1390060A2 (fr) 2004-02-25

Similar Documents

Publication Publication Date Title
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
WO2005103041A3 (fr) Traitement des troubles du systeme nerveux central au moyen de modulateurs cibles du snc
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
WO2004032877A3 (fr) Compositions, organismes et methodologies utilisant une nouvelle kinase humaine
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2002058724A8 (fr) Utilisation de lp82 pour traiter les problemes de poids
WO2003033557A3 (fr) Copolymeres fluores, leur production et leur utilisation
WO2002039997A3 (fr) Composes modulant ace-2 et procedes d'utilisation associes
WO2005112903A3 (fr) Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
WO2004067510A8 (fr) Derives de 3,6-disubstitues azabicyclo hexane utilises en tant qu'antagonistes du recepteur de muscarinique
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2004091646A3 (fr) Compositions de slurp-1 et leurs methodes d'utilisation
WO2006028492A3 (fr) Hc1q/tnf7 et ses utilisations
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
WO2002060382A3 (fr) Composes et utilisations
WO2004078130A3 (fr) Proteines d'interaction posh et procedes connexes
EP1440080A4 (fr) Methodes et compositions servant au diagnostic et au traitement de troubles de la proliferation cellulaire impliquant le 20750
WO2002068614A3 (fr) Protéine du facteur régulateur de l'interféron-1/de fusion réceptrice d'oestrogene humain et son utilisation dans le traitement des carcinomes
WO2003033534A3 (fr) Polynucleotides et polypeptides ngzipa, ngzipd, pgzipa et pgzipd et utilisations de ceux-ci
IL159081A0 (en) Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU2003290560A1 (en) Inmould process for the spheroidization and inoculation treatment of cast sg iron
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10466695

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002720768

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002720768

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWW Wipo information: withdrawn in national office

Ref document number: 2002720768

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载